We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Groundbreaking Genomics Method to Improve Early Detection of Genetic Diseases

By LabMedica International staff writers
Posted on 02 Dec 2024

Researchers using next-generation sequencing are uncovering valuable insights from the non-coding segments of human DNA, which were once considered "junk DNA. More...

" These segments, called non-coding RNAs, hold critical information on the presence of diseases. In a new approach, scientists are working to adapt laboratory equipment initially designed to analyze only mRNA, the coding parts of genetic material, and also examine the non-coding regions of DNA. This innovative genomics technique could reveal the genetic mechanisms behind both human health and diseases, offering a potential method for early detection of conditions like cancer and dementia. The research, published in Genome Biology, proposes a novel approach to exploring the root causes of various diseases.

Over the past two decades, researchers have used advanced tools to analyze non-coding RNAs and identify the 3% of sequences that are coded. As part of the Canadian Epitranscriptomics Project, scientists at the University of Manitoba (Winnipeg, Canada) are leveraging this technology to create the "Epitranscriptome Atlas," which aims to map the remaining 97% of the human genome. This effort will enhance our understanding of how alterations in non-coding RNAs contribute to disease.

“My lab applies what we call next-generation sequencing and bioinformatics to magnify the impact of recent advances in AI algorithms,” said Dr. Athanasios Zovoilis, associate professor of biochemistry and medical genetics in the Max Rady College of Medicine. “The right equipment for this new field of study has been in our lab for some time, but we lacked the tools to use it to its fullest potential, until now. The impact of employing AI and novel genomics approaches is that researchers across the world can now leverage next-generation sequencing in the new field of epitranscriptomics, exploring the genetic interactions of non-coding RNAs.”

“If we imagine the human genome as an atlas of the earth, with each gene represented by one satellite image, we have so far revealed fewer than 36,000 of the necessary 1.2 million images to complete our atlas. The mapped RNA sequences represent specific human tissues, and we are now able to begin filling in large sections of our atlas to pinpoint the genomic locations of diseases and other important biological functions for the first time,” Zovoilis added.

 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Urine Analyzer
respons® UDS100
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.